During the last session, Sensei Biotherapeutics Inc (NASDAQ:SNSE)’s traded shares were 0.42 million, with the beta value of the company hitting 0.08. At the end of the trading day, the stock’s price was $0.52, reflecting an intraday gain of 7.67% or $0.04. The 52-week high for the SNSE share is $1.94, that puts it down -273.08 from that peak though still a striking 26.92% gain since the share price plummeted to a 52-week low of $0.38. The company’s market capitalization is $13.10M, and the average intraday trading volume over the past 10 days was 0.47 million shares, and the average trade volume was 374.66K shares over the past three months.
Sensei Biotherapeutics Inc (SNSE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SNSE has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Sensei Biotherapeutics Inc (NASDAQ:SNSE) trade information
Sensei Biotherapeutics Inc (SNSE) registered a 7.67% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.67% in intraday trading to $0.52, hitting a weekly high. The stock’s 5-day price performance is 14.91%, and it has moved by -11.68% in 30 days. Based on these gigs, the overall price performance for the year is -20.58%. The short interest in Sensei Biotherapeutics Inc (NASDAQ:SNSE) is 0.19 million shares and it means that shorts have 0.29 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 90.55% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $6 respectively. As a result, SNSE is trading at a discount of -1053.85% off the target high and -861.54% off the low.
Sensei Biotherapeutics Inc (SNSE) estimates and forecasts
Statistics show that Sensei Biotherapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Sensei Biotherapeutics Inc (SNSE) shares have gone down -34.04% during the last six months, with a year-to-date growth rate less than the industry average at 5.74% against 17.90.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -16.26%. While earnings are projected to return 4.10% in 2024.
SNSE Dividends
Sensei Biotherapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sensei Biotherapeutics Inc (NASDAQ:SNSE)’s Major holders
Sensei Biotherapeutics Inc insiders own 34.39% of total outstanding shares while institutional holders control 8.81%, with the float percentage being 13.43%. IKARIAN CAPITAL, LLC is the largest shareholder of the company, while 23.0 institutions own stock in it. As of 2024-06-30, the company held over 0.65 million shares (or 2.5949% of all shares), a total value of $0.4 million in shares.
The next largest institutional holding, with 0.62 million shares, is of VANGUARD GROUP INC’s that is approximately 2.4702% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.38 million.
Also, the Mutual Funds coming in first place with the largest holdings of Sensei Biotherapeutics Inc (SNSE) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 485.96 shares. This amounts to just over 1.93 percent of the company’s overall shares, with a $0.25 million market value. The same data shows that the other fund manager holds slightly less at 99.62, or about 0.40% of the stock, which is worth about $51909.0.
